Executive Vice President and Chief Financial Officer - Joseph J. Wolk Executive Vice President, Worldwide Chairman, ...

Johnson & Johnson (NYSE: JNJ) announced today the U.S. launch of its Shockwave C2 Aero Fly Coronary IVL Catheter designed to ...

Scientists are engineering oral peptides to survive digestion and reach specific targets in the body, potentially paving the way for new precision medicines.

Johnson & Johnson reported Q3 revenue beats but missed adjusted earnings expectations.MedTech international sales and ...

Below are the CEO and CFO prepared remarks from Johnson & Johnson's third-quarter 2026 earnings call. For the complete transcript, financial results, supplemental materials and additional information, ...

Q3 2026 earnings call recap: raised 2026 sales guidance, EPS outlook, MedTech risks, talc update and catalysts—read key takeaways.

Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Johnson & Johnson (“Johnson & Johnson” or “the ...

"Targeted oral peptides are unique in that just a small amount of the drug is absorbed from the dose that is given." ...

Johnson & Johnson will showcase digital surgery technologies and its strategic collaboration with the Department of Health – Abu Dhabi (DOH), to advance surgical intelligence at the Abu Dhabi Future ...

Welcome to our company's review of business results for the first quarter of 2026 and our financial outlook for the full year. First, a few logistics. As a reminder, today's presentation and ...

Discover how scientists are redesigning peptides to withstand digestion, target specific cells and potentially bring ...